Shares of Esperion Therapeutics Inc. were down 1.5% in premarket trading on Monday after the company said it plans to reduce its workforce by 40%, citing the challenges of launching two cholesterol-lowering medications during the pandemic. It also said it plans to streamline its commercial strategy, and with those programs in place, Esperion expects to save at least $20 million in 2021. Research and development expenses are now expected to be $110 to $115 million in 2021, down from previous guidance of $120 to $130 million, and selling, general and administrative expenses are expected to be $195 to $200 million this…
